GIKLY Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 geg. 2024 @ 18:25):

Stats
Šios dienos apimtis	1 206.00
Vidutinė apimtis	3 211.00
Rinkos kapitalizacija	6.14B
EPS	$0 ( 2023-09-30 )
Kita pelno data	( $0 ) 2024-06-14
Last Dividend	$0.222 ( 2021-06-03 )
Next Dividend	$0 ( N/A )
P/E	96.60
ATR14	$0 (0.00%)

Grifols, S.A. Koreliacija

10 Labiausiai teigiamai susiję koreliacijos

10 Labiausiai neigiamai susiję koreliacijos

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Grifols, S.A. Finansinės ataskaitos

Annual	2023
Pajamos:	$6.59B
Bruto pelnas:	$2.32B (35.24 %)
EPS:	$0.0873

FY	2023
Pajamos:	$6.59B
Bruto pelnas:	$2.32B (35.24 %)
EPS:	$0.0873

FY	2022
Pajamos:	$6.06B
Bruto pelnas:	$2.23B (36.80 %)
EPS:	$0.310

FY	2021
Pajamos:	$4.93B
Bruto pelnas:	$1.96B (39.78 %)
EPS:	$0.133

Financial Reports:

No articles found.

Grifols, S.A. Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Grifols, S.A. Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 5.88 - average (63.08%) | Divividend Growth Potential Score: 2.23 - No dividend growth expected in the near future

Information

First Dividend	$0.0385	2010-06-28
Last Dividend	$0.222	2021-06-03
Next Dividend	$0	N/A
Payout Date	2021-06-14
Next Payout Date	N/A
# dividends	16	--
Total Paid Out	$1.516	--
Avg. Dividend % Per Year	0.00%	--
Score	1.88	--
Div. Sustainability Score	5.88
Div.Growth Potential Score	2.23
Div. Directional Score	4.05	--

Next Divdend (Est)
(2024-06-20)

$0 Estimate 0.00 %

Dividend Stability

0.06 Very Bad

Dividend Score

1.88

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield

Dividend Commentary

With a moderate Dividend Sustainability Score (DSS), the company may sustain its dividends, but continuous monitoring is advised for any financial shifts. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for OTC

Symbol	Title	Last dividend	Frequency	Yearly Dividend
SOBS	Ex Dividend Knight	2023-06-29	Quarterly	0.00%
GTMEY	Ex Dividend Knight	2023-08-28	Quarterly	0.00%
AGRIP	Ex Dividend Knight	2023-08-31	Quarterly	0.00%
NHMD	Ex Dividend Junior	2023-08-30	Semi-Annually	0.00%
CNTHP	Ex Dividend Knight	2023-07-07	Quarterly	0.00%
THNPY	Ex Dividend Knight	2023-05-18	Annually	0.00%
HSNGY	Ex Dividend Knight	2023-08-11	Quarterly	0.00%
ASHTY	Ex Dividend Knight	2023-08-10	Semi-Annually	0.00%
PHPPY	Ex Dividend Junior	2023-05-18	Annually	0.00%
DSKYF	Ex Dividend Knight	2023-09-28	Annually	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.0251	1.500	9.50	10.00	[0 - 0.5]
returnOnAssetsTTM	0.00769	1.200	9.74	10.00	[0 - 0.3]
returnOnEquityTTM	0.0279	1.500	-0.801	-1.202	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	2.79	0.800	1.069	0.855	[1 - 3]
quickRatioTTM	0.629	0.800	-1.006	-0.805	[0.8 - 2.5]
cashRatioTTM	0.229	1.500	9.84	10.00	[0.2 - 2]
debtRatioTTM	0.425	-1.500	2.92	-4.38	[0 - 0.6]
interestCoverageTTM	2.33	1.000	-0.248	-0.248	[3 - 30]
operatingCashFlowPerShareTTM	0.307	2.00	9.90	10.00	[0 - 30]
freeCashFlowPerShareTTM	-0.0538	2.00	-0.0269	-0.0538	[0 - 20]
debtEquityRatioTTM	1.564	-1.500	3.74	-5.62	[0 - 2.5]
grossProfitMarginTTM	0.381	1.000	6.99	6.99	[0.2 - 0.8]
operatingProfitMarginTTM	0.135	1.000	9.30	9.30	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.0229	1.000	-0.984	-0.984	[0.2 - 2]
assetTurnoverTTM	0.306	0.800	-1.291	-1.033	[0.5 - 2]
Total Score				5.88

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	18.47	1.000	8.24	0	[1 - 100]
returnOnEquityTTM	0.0279	2.50	-0.515	-1.202	[0.1 - 1.5]
freeCashFlowPerShareTTM	-0.0538	2.00	-0.0179	-0.0538	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	0.307	2.00	9.90	10.00	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	1.292	1.500	4.72	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.0317	1.000	-1.708	0	[0.1 - 0.5]
Total Score				2.23

Grifols, S.A.

Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others divisions. The Bioscience division researches, develops, produces, and markets plasma-derived medicines and other innovative solutions to treat patients with chronic, rare, prevalent, and life-threatening diseases. It offers immunoglobulins, alpha-1 antitrypsin, albumin, clotting factors, and hyperimmune globulins. The Hospital division offers non-biological pharmaceutical products and medical supplies clinical nutrition, intravenous therapy, and medical devices. The Diagnostic division researches, develops, produces, and commercializes diagnostic products that span the healthcare continuumfrom prevention, screening, diagnosis, and prognosis to disease and treatment monitoringto serve professionals. The Bio Supplies division provides biological materials for life-science research, clinical trials, and for manufacturing pharmaceutical and diagnostic products. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves public and private customers; and wholesalers, distributors, group purchasing organizations, blood banks, hospitals and care institutions, and national health systems. Grifols, S.A. has a technology collaboration agreement with Mondragon. The company was founded in 1940 and is headquartered in Barcelona, Spain.